Bank of Montreal
ALXN

Bank of Montreal’s Alexion Pharmaceuticals ALXN Stock Holding History

Bank of Montreal’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-30,000
Closed -$3.34M – 4937
2018
Q1 		$3.34M Buy
+30,000
New +$3.59M ﹤0.01% 1335

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Bank of Montreal's ALXN Position: Q3 2021 in Review

Bank of Montreal sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 839,239 shares — an estimated $155M sold.

Bank of Montreal first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $182M in Q4 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Bank of Montreal reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Bank of Montreal sold 839,239 Alexion Pharmaceuticals shares in Q3 2021, an estimated $155M.
  • Bank of Montreal first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Bank of Montreal's Alexion Pharmaceuticals position peaked at $182M in Q4 2017.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Bank of Montreal's 13F filing for Q3 2021, filed 12 Nov 2021.